SCHEMBL2279848

SCHEMBL2279848

Cc1nnc2c3cc(-c4ccccc4)c(-c4ccc(CO)cc4)nc3ccn12

nearest known ligand 0.54

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
AKT1 P31749 13/20 0.54
AKT2 P31751 11/20 0.54
KCNH2 Q12809 4/20 0.54
AKT3 Q9Y243 2/20 0.42
FECH P22830 1/20 0.42
HSD17B10 Q99714 2/20 0.40
MEN1 O00255 1/20 0.40
POLB P06746 1/20 0.40
KMT2A Q03164 1/20 0.40
TSHR P16473 1/20 0.39
MAPK1 P28482 1/20 0.39
BAZ2B Q9UIF8 1/20 0.39
BAZ2A Q9UIF9 1/20 0.39
KDM4E B2RXH2 1/20 0.37
HTT P42858 1/20 0.37
BRD4 O60885 1/20 0.37
H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 P62805 1/20 0.37
DHODH Q02127 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2283320 0.90 AKT1 (0.53) AKT1AKT2KCNH2AKT3FECH
Hydrochloric Acid SCHEMBL3504287 0.89 AKT1 (0.53) AKT1AKT2KCNH2AKT3FECH
SCHEMBL2278868 0.85 AKT1 (0.48) AKT1AKT2KCNH2AKT3FECH
SCHEMBL2282352 0.85 AKT1 (0.44) AKT1AKT2KCNH2AKT3FECH
SCHEMBL2284492 0.84 AKT1 (0.47) AKT1AKT2KCNH2AKT3FECH
SCHEMBL2287763 0.84 AKT1 (0.47) AKT1AKT2KCNH2AKT3FECH
SCHEMBL12410150 0.84 AKT1 (0.47) AKT1AKT2KCNH2AKT3FECH
SCHEMBL2279249 0.84 ALDH1A1 (0.47) AKT1AKT2KCNH2MEN1KMT2A
SCHEMBL2284105 0.84 AKT1 (0.47) AKT1AKT2KCNH2AKT3FECH
SCHEMBL3504691 0.84 AKT1 (0.47) AKT1AKT2KCNH2AKT3FECH

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1898903-B1 INHIBITORS OF AKT ACTIVITY MERCK SHARP & DOHME (US) 2013-03-27 EP claimed
US-8008317-B2 Inhibitors of akt activtiy MERCK SHARP & DOHME CORP. (US) 2011-08-30 US claimed
US-20100222321-A1 Inhibitors of akt activtiy MERCK SHARP & DOHME LLC 2010-09-02 US claimed
EP-1898903-B1 INHIBITORS OF AKT ACTIVITY MERCK SHARP & DOHME (US) 2013-03-27 EP disclosed
US-8008317-B2 Inhibitors of akt activtiy MERCK SHARP & DOHME CORP. (US) 2011-08-30 US disclosed
US-8008317-B2 Inhibitors of akt activtiy MERCK SHARP & DOHME CORP. (US) 2011-08-30 US disclosed
US-8008317-B2 Inhibitors of akt activtiy MERCK SHARP & DOHME CORP. (US) 2011-08-30 US disclosed
US-20100222321-A1 Inhibitors of akt activtiy MERCK SHARP & DOHME LLC 2010-09-02 US disclosed
US-20100222321-A1 Inhibitors of akt activtiy MERCK SHARP & DOHME LLC 2010-09-02 US disclosed
US-20100222321-A1 Inhibitors of akt activtiy MERCK SHARP & DOHME LLC 2010-09-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100222321-A1 Inhibitors of akt activtiy PIK3CA, PIK3CD, INPP5D AKT1 8/4885AKT2 4/4885KCNH2 3672/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.